**Result tables**

**Table 3A. Main and incremental results per strategy and model**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Results per 1000 BE patients | NH | S | *Incremental results compared to NH* | HGD | *Incremental results compared to S* | LGD | *Incremental results compared to HGD* | BE | *Incremental results compared to HGD\* or LGD* |
| FHCRC |  |  |  |  |  |  |  |  |  |
| Number of surveillance endoscopies | 0 | 5435 | *+5435* | 7077 | *+1642* |  |  | 8798 | *1721* |
| Number treatments | 0 | 0 |  | 703 | *+703* |  |  | 4795 | *+4092* |
| Number of EAC cases | 132 | 171 | *+30%* | 88 | *-48%* |  |  | 20 | *-78%* |
| Number of EAC deaths | 100 | 84 | *-16%* | 45 | *-46%* |  |  | 13 | *-72%* |
| Average life expectancy after diagnosis (years) | 19.2 | 19.3 |  | 19.6 |  |  |  | 19.9 |  |
| Number of complications | 0 | 0.7 | *+0.7* | 39.1 | *+38.4* |  |  | 247.1 | *+208* |
| MGH |  |  |  |  |  |  |  |  |  |
| Number of surveillance endoscopies | 0 | 7177 | *+7177* | 7840 | *+664* | 8911 | 1071 | 9678 | *767* |
| Number treatments | 0 | 0 | *+0* | 864 | *+864* | 3039 | +2175 | 4978 | *+1939* |
| Number of EAC cases | 85 | 109 | *+29%* | 51 | *-53%* | 39 | -25% | 29 | *-24%* |
| Number of EAC deaths | 57 | 42 | *-28%* | 21 | *-48%* | 16 | -24% | 12 | *-28%* |
| Average life expectancy after diagnosis (years) | 20.4 | 20.6 |  | 20.8 |  | 20.8 |  | 20.9 |  |
| Number of complications | 0 | 0.9 | *+0.9* | 51.6 | *+50.7* | 170.3 | +118.7 | 247.3 | *+76.9* |
| Erasmus/UW |  |  |  |  |  |  |  |  |  |
| Number of surveillance endoscopies | 0 | 8430 | *+8430* | 6473 | *+-1956* | 6083 | -391 | 7332 | *1249* |
| Number treatments | 0 | 0 | *+0* | 1265 | *+1265* | 2593 | +1328 | 5998 | *+3405* |
| Number of EAC cases | **68** | 94 | *+39%* | 45 | *-53%* | 33 | -25% | 25 | *-24%* |
| Number of EAC deaths | 49 | 38 | *-21%* | 22 | *-41%* | 16 | -28% | 9 | *-44%* |
| Average life expectancy after diagnosis (years) | 20.5 | 20.6 |  | 20.8 |  | 20.9 |  |  |  |
| Number of complications | 0 | 1.1 | *+1.1* | 50.0 | *+48.9* | 106.7 | +56.7 | 247.0 | *+140.2* |
| Average all models | NH | S |  | HGD |  | LGD |  | BE |  |
| Number of surveillance endoscopies | - | 7,014 |  | 7,130 |  | 7,497 |  | 8,603 |  |
| Number treatments | - | - |  | 944 |  | 2816 |  | 5257 |  |
| Number of EAC cases | 95 | 125 |  | 61 |  | 36 |  | 25 |  |
| Number of EAC deaths | 69 | 55 |  | 30 |  | 16 |  | 11 |  |
| Average life expectancy after diagnosis (years) | 20.0 | 20.1 |  | 20.4 |  | 20.8 |  | 20.6 |  |
| Number of complications | - | 0.9 |  | 46.9 |  | 138.5 |  | 247.1 |  |

EAC: esophageal adenocarcinoma, Strategies: NH:Natural History strategy; S: Surveillance strategy,HGD: Endoscopic ablative therapy for HGD diagnosed patients strategy; LGD: Endoscopic ablative therapy for dysplasia diagnosed patients strategy; BE: Endoscopic ablative therapy for all BE diagnosed patients strategy

\* The incremental results for the FHCRC model are compared to the HGD strategy, while for the other groups these results are compared to the LGD strategy

**3B. Incremental numbers needed to treat to prevent one EAC death per strategy and model**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Incremental NNT/Death | **FHCRC** | | | **MGH** | | | **ERASMUS/UW** | |  |
|  | Reference strategy | | | Reference strategy | | | Reference strategy | | |
| Strategy: | S | HGD | LGD | S | HGD | LGD | S | HGD | LGD |
| HGD | 18 |  |  | 43 |  |  | 79 |  |  |
| LGD |  |  |  | 120 | 417 |  | 117 | 210 |  |
| BE | 67 | 127 |  | 167 | 421 | 425 | 204 | 351 | 476 |

EAC: esophageal adenocarcinoma, Strategies: NH:Natural History strategy; S: Surveillance strategy, HGD: Endoscopic ablative therapy for HGD diagnosed patients strategy; LGD: Endoscopic ablative therapy for dysplasia diagnosed patients strategy; BE: Endoscopic ablative therapy for all BE diagnosed patients strategy

**Table 3C. Incremental Cost Effectiveness Ratio per BE patient**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Costs** | **QALYs** | **ICER non-dominated** |
| FHCRC |  |  |  |
| NH | $ 7,221 | 14.33 |  |
| HGD | $ 12,762 | 14.58 |  |
| BE | $ 13,234 | 14.71 | $ 15,834 |
| surveillance | $ 17,848 | 14.34 |  |
|  |  |  |  |
| MGH |  |  |  |
| NH | $ 4,839 | 14.77 |  |
| HGD | $ 8,867 | 14.98 | $ 19,705 |
| LGD | $ 11,474 | 14.99 | $ 178,955 |
| surveillance | $ 12,202 | 14.85 |  |
| BE | $ 14,338 | 15.00 | $ 194,160 |
|  |  |  |  |
| ErasmusUW |  |  |  |
| NH | $ 3,946 | 14.82 |  |
| HGD | $ 7,395 | 15.00 | $ 18,586 |
| LGD | $ 8,279 | 15.03 | $ 30,219 |
| surveillance | $ 10,235 | 14.89 |  |
| BE | $ 13,156 | 15.04 | $ 395,557 |

NH:Natural History strategy; S: Surveillance strategy,HGD: Endoscopic ablative therapy for HGD diagnosed patients strategy; LGD: Endoscopic ablative therapy for dysplasia diagnosed patients strategy; BE: Endoscopic ablative therapy for all BE diagnosed patients strategy